Levrett Plc – Jazz Pharmaceuticals agrees $30.25 per share bid for Celator Pharmaceuticals Inc which traded at $1.50 as recently as March

With headlines like this from (Jazz Pharmaceuticals plc – NASDAQ:JAZZ) we knew it wouldn’t go unnoticed by Levrett Plc (LON:LVRT) CEO Pascal Hughes, who we caught up with to ask his thoughts.

 

“This is an eye-catching deal even by the standards of biotech M&A of the past few years, a 72% premium to Friday’s closing price and the stock traded at $1.50 as recently as March 2016, before Celator announced positive results from it’s leukaemia drug trial and then successfully attained ‘orphan’ designation, a reminder that companies that successfully develop good science can command big premiums and generate very high returns for investors, regardless of where we are in the overall cycle.
The company is still pre-revenue demonstrating that big pharma continue to be willing to pay substantial premiums for promising treatments at the pre-approval stage.
Furthermore, in the case of Jazz, they are seeking to address the coming patent expiry on their principal revenue earning drug though M&A, a continuation of one of the major drivers of transactions and here valuations, in the sector in recent years – the strategic imperative of replacing expiring patents and hence revenue streams and building up a portfolio of therapies in a particular sector.” – Pascal Hughes CEO Levrett Plc.

 

Levrett plc is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies focused in the Pharmaceutical and Biotechnology sector. The Company draws on its expertise in the Pharmaceutical and Biotechnology sector to assess different propositions and initiate discussions via market contacts and professional advisers. In selecting acquisition opportunities to review, the Board will focus on entities that are available at attractive valuations and hold opportunities to unlock embedded value.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Levrett Plc

    More articles like this

    Levrett Plc

    Levrett Plc Final Results and Annual Report

    Levrett PLC (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today announced its final results for the period ended 31 March 2017 and

    Levrett Plc

    Levrett Plc Biotech: Bull market or Bubble?

    Levrett Plc (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today made the following comment regarding the Timmerman Report which was published earlier

    Levrett Plc

    Levrett Plc Big data in biotech

    Alphabet Inc (NASDAC:GOOGL) executive chairman Eric Schmidt on Monday pointed out six game changing technologies, or what he calls moonshots, that he thinks will improve important parts of society. This was highlighted on the fortune.com website.

    Levrett Plc

    Levrett Plc comments on an unprecedented cancer research effort

    Levrett Plc (LON:LVRT) CEO Pascal Hughes, said: “Sean Parker of Napster and Facebook fame joins a list of tech based philanthropists starting initiatives in the Biotech and Lifescience sector with this collaborative initiative in immuno-oncology which

    Levrett Plc

    Levrett Plc Strategy, Biotechnology, Success and Focus

    Levrett Plc (LON:LVRT) Chief Executive Officer Pascal Hughes caught up with DirectorsTalk to chat about strategy, the biotech sector, the future for this sector and due diligence. Levrett Plc, a Company formed to acquire a target